EQIX vs STRO · P/E 79, rev $9.22B vs rev $62.0M
Equinix Inc (EQIX) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Equinix Inc (EQIX) is a reit - specialty company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported EQIX revenue for 2025-12-31 was $9.22B. Net income was $1.35B. Revenue was up 5.4% from 2024-12-31 to 2025-12-31. EQIX currently screens at market cap $74.23B and trailing P/E 79.4.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
EQIX currently screens at market cap $74.23B and trailing P/E 79.4. STRO currently screens at market cap $470.8M.
Not investment advice. Open the EQIX and STRO stock pages for the full models.
Not investment advice.